



Substrate Activity Screening with Kinases: Discovery of
Small-Molecule Substrate-Competitive c-Src Inhibitors**










TABLE	  OF	  CONTENTS	  
	  
I. General	  Synthetic	  Methods	   	   	   	   	   	   	   	   	  S2	  
II. Synthesis	  of	  Compounds	  7-­‐12	   	   	   	   	   	   	   	   	  S2	  
III. Spectral	  Data	  for	  Compounds	  7-­‐12	   	   	   	   	   	   	   	  S6	  
IV. Gas	  Chromatography	  Traces	  for	  Compounds	  7-­‐12	   	   	   	   	   S15	  
V. Biochemical	  Substrate	  Identification	  Assays	   	   	   	   	   	   S18	  
VI. Biochemical	  Characterization	  of	  Inhibitors	  7-­‐12	   	   	   	   	   	   S40	  
VII. Computational	  Docking	  Methods	  and	  Model	   	   	   	   	   	   S64	  
VIII. Kinase	  Mutant	  Production	   	   	   	   	   	   	   	   S66	  
IX. In	  Cellulo	  Characterization	  of	  12	  	   	   	   	   	   	   	   S67	  

























I.	  	  GENERAL	  SYNTHETIC	  METHODS	  
Unless	  otherwise	  noted,	   all	   reagents	  were	  obtained	  via	   commercial	   sources	  and	  used	  without	   further	  
purification.	   1H,	   13C,	   and	   19F	   NMR	   spectra	   were	   measured	   with	   a	   Varian	   MR400	   or	   Inova	   500	  
spectrometer.	   Mass	   Spectrometry	   (HRMS)	   was	   carried	   out	   by	   the	   University	   of	   Michigan	   Mass	  
Spectrometry	  Facility	  (J.	  Windak,	  director).	  
	  




2,3,5,6-­‐tetrafluoro-­‐4-­‐(phenylamino)phenol	  (7).	  	  Compound	  7	  was	  prepared	  in	  a	  manner	  similar	  to	  that	  
described	   by	   Maiti	   and	   Buchwald.1	   To	   an	   oven-­‐dried	   4	   mL	   conical	   vial	   was	   added	   4-­‐bromo-­‐2,3,5,6-­‐
tetrafluorophenol	   (123	  mg,	  0.5	  mmol),	   aniline	   (55	  µL,	   0.6	  mmol),	   sodium	   tert-­‐butoxide	   (120	  mg,	  1.25	  
mmol),	   and	   BrettPhos	   palladacycle	   (0.8	   mg,	   0.001	   mmol).	   	   The	   vial	   was	   flushed	   with	   N2,	   then	   1	   mL	  
anhydrous	  1,4-­‐dioxane	  was	  added.	   	  The	   reaction	  was	   stirred	  at	  90	  C	   for	  3	  h.	   	  After	   cooling	   to	  RT,	   the	  
reaction	  was	  poured	   into	  a	  10%	  aqueous	  citric	  acid	  solution	  (30	  mL)	  and	  extracted	  with	  EtOAc	  (4	  x	  20	  
mL).	   	   The	   organic	   extracts	   were	   dried	   over	   MgSO4	   and	   the	   solvent	   was	   removed	   under	   reduced	  
pressure.	   	   Purification	   by	   automated	   silica	   gel	   chromatography	   using	   a	   6	   →	   60%	   EtOAc	   in	   hexanes	  
gradient	  afforded	  6	   as	  a	  pale	  yellow	  crystalline	   solid	   (36	  mg,	  28%	  yield).	   	   1H	  NMR	   (400	  MHz,	  CDCl3)	  δ	  
7.28	  –	  7.14	   (m,	  2H),	   6.96	  –	  6.86	   (m,	  1H),	   6.74	   (m,	  2H),	   5.51	   (s,	   1H),	   5.23	   (s,	   1H).	   	   19F	  NMR	   (400	  MHz,	  
CDCl3)	  δ	  -­‐149.9	  (dd,	  J	  =	  23.7	  Hz,	  7.2	  Hz,	  2F),	  -­‐163.8	  (dd,	  J	  =	  23.7	  Hz,	  7.2	  Hz,	  2F).	  	  HRMS-­‐ESI	  (m/z):	  [M+H]+	  






N-­‐phenylpyridin-­‐4-­‐amine	   (S1).	   	  To	  an	  oven-­‐dried	  vial	  was	  added	  4-­‐aminopyridine	  (113	  mg,	  1.2	  mmol),	  
bromobenzene	   (106	   µL,	   1.0	   mmol),	   Cs2CO3	   (814	   mg,	   2.5	   mmol),	   Xantphos	   (58	   mg,	   0.1	   mmol),	   and	  
Pd2(dba)3	   (46	  mg,	  0.05	  mmol).	   	  The	  vial	  was	  flushed	  with	  N2	   for	  5	  min,	   then	  anhydrous	  1,4-­‐dioxane	  (4	  
mL)	   was	   added	   and	   the	   reaction	   was	   stirred	   at	   95	   C	   for	   24	   h.	   	   The	   reaction	   was	   cooled	   to	   room	  
temperature,	   diluted	  with	   H2O	   (30	  mL),	   and	   extracted	  with	   EtOAc	   (3x20	  mL).	   	   The	   combined	   organic	  
extracts	   were	   dried	   over	   MgSO4,	   filtered,	   and	   the	   solvent	   was	   removed	   under	   reduced	   pressure.	  	  
Purification	  by	  automated	  silica	  gel	  chromatography	  using	  a	  0	  →	  10%	  MeOH	  in	  DCM	  gradient	  afforded	  
S1	  as	  a	   light	  yellow	  solid	  (133	  mg,	  78%	  yield).	   	  1H	  NMR	  (500	  MHz,	  CDCl3)	  δ	  8.28	  –	  8.23	  (m,	  2H),	  7.39	  –	  
7.31	  (m,	  2H),	  7.21	  –	  7.08	  (m,	  3H),	  6.83	  –	  6.77	  (m,	  2H),	  6.14	  (s,	  1H).	  	  13C	  NMR	  (125	  MHz,	  CDCl3)	  δ	  150.83,	  
149.91,	  139.50,	  129.52,	  124.12,	  121.63,	  109.41.	   	  HRMS-­‐ESI	  (m/z):	   [M+H]+	  calcd	  for	  C11H10N2,	  171.0917;	  
found	  171.0916.	  
	  
Tert-­‐butylphenyl(pyridin-­‐4-­‐yl)carbamate	   (S2).	   	   In	  a	  25	  mL	  roundbottom	  flask,	  S1	   (100	  mg,	  0.59	  mmol)	  
was	  dissolved	  in	  6	  mL	  anhydrous	  THF.	   	  TEA	  (160	  µL,	  1.2	  mmol)	  was	  added	  followed	  by	  DMAP	  (0.7	  mg,	  
0.006	  mmol)	  and	  Boc2O	  (154	  mg,	  0.71	  mmol).	  	  The	  reaction	  was	  stirred	  at	  room	  temperature	  overnight	  
then	   at	   65	  C	   for	   24	   h.	   	   The	   reaction	  was	   cooled	   to	   room	   temperature,	   diluted	  with	  H2O	   (30	  mL)	   and	  
extracted	  with	  EtOAc	  (3x15	  mL).	   	  The	  combined	  organic	  extracts	  were	  dried	  over	  MgSO4,	   filtered,	  and	  
the	  solvent	  was	  removed	  under	  reduced	  pressure.	  	  Purification	  by	  automated	  silica	  gel	  chromatography	  
using	  a	  10	  →	  80%	  EtOAc	  in	  hexanes	  gradient	  afforded	  S2	  as	  a	  white	  solid	  (52	  mg,	  32%	  yield).	  	  1H	  NMR	  
(500	  MHz,	  CDCl3)	  δ	  8.43	  –	  8.38	  (m,	  2H),	  7.43	  –	  7.35	  (m,	  2H),	  7.35	  –	  7.27	  (m,	  1H),	  7.18	  –	  7.10	  (m,	  4H),	  1.42	  
(s,	   9H).	   	   13C	  NMR	   (125	  MHz,	  CDCl3)	  δ	  152.83,	  150.11,	  150.04,	  140.99,	  129.38,	  128.30,	  127.42,	  117.78,	  
82.30,	  28.04.	  	  HRMS-­‐ESI	  (m/z):	  [M+H]+	  calcd	  for	  C16H18N2O2,	  271.1441;	  found	  271.1443.	  
	  
4-­‐((tert-­‐butoxycarbonyl)(phenyl)amino)pyridine	  1-­‐oxide	  (S3).	  	  S2	  (41	  mg,	  0.15	  mmol)	  was	  dissolved	  in	  5	  
mL	  DCM	  then	  mCPBA	  (104	  mg,	  0.6	  mmol)	  was	  added.	  	  The	  reaction	  was	  stirred	  at	  room	  temperature	  for	  
20	  h.	   	  The	  reaction	  was	  diluted	  with	  10	  mL	  DCM	  and	  washed	  with	  1	  N	  NaOH	  (15	  mL),	  and	  the	  organic	  
layer	  was	  dried	  over	  MgSO4,	  filtered,	  and	  the	  solvent	  was	  removed	  under	  reduced	  pressure.	  Purification	  
by	  automated	  silica	  gel	  chromatography	  using	  a	  0	  →	  7%	  MeOH	  in	  DCM	  gradient	  afforded	  S3	  as	  a	   light	  
yellow	  glass	  (38	  mg,	  89%	  yield).	   	  1H	  NMR	  (500	  MHz,	  CDCl3)	  δ	  8.07	  –	  8.00	  (m,	  2H),	  7.45	  –	  7.37	  (m,	  2H),	  
7.37	   –	   7.30	   (m,	   1H),	   7.20	   –	   7.11	   (m,	   4H),	   1.40	   (s,	   9H).	   	   13C	   NMR	   (125	  MHz,	   CDCl3)	   δ	   152.40,	   141.55,	  
140.25,	   138.70,	   129.61,	   127.98,	   127.80,	   119.80,	   82.82,	   27.91.	   	   HRMS-­‐ESI	   (m/z):	   [M+H]+	   calcd	   for	  
C16H18N2O3,	  287.1390;	  found	  287.1393.	  
	  
4-­‐(phenylamino)pyridine	   1-­‐oxide	   (8).	   	   In	  a	  dry	  10	  mL	   round	  bottom	  flask	   S3	   (30	  mg,	  0.10	  mmol)	  was	  
dissolved	  in	  4	  mL	  DCM	  then	  TFA	  (2	  mmol)	  was	  added.	  	  The	  reaction	  was	  stirred	  at	  reflux	  for	  24	  h,	  then	  
the	  solvent	  was	  removed	  under	  reduced	  pressure.	  	  Purification	  by	  automated	  silica	  gel	  chromatography	  
using	  a	  0	  →	  7%	  MeOH	  in	  DCM	  gradient	  afforded	  8	  as	  a	  light	  brown	  solid	  (8	  mg,	  41%	  yield).	  	  1H	  NMR	  (500	  
MHz,	  DMSO-­‐d6)	  δ	  9.08	  (s,	  1H),	  8.01	  –	  7.95	  (m,	  2H),	  7.35	  (t,	  J	  =	  7.8	  Hz,	  2H),	  7.16	  (d,	  J	  =	  7.9	  Hz,	  2H),	  7.04	  (t,	  
J	  =	  7.4	  Hz,	  1H),	  6.98	  –	  6.91	   (m,	  2H).	   	   13C	  NMR	   (125	  MHz,	  DMSO-­‐d6)	  δ	  143.83,	  140.00,	  139.14,	  129.54,	  





5-­‐(phenylamino)pyridin-­‐2(1H)-­‐one	   (9).	   	   Compound	   9	   was	   prepared	   in	   a	   manner	   similar	   to	   that	  
described	  by	  Maiti	  and	  Buchwald.	  1	  	  To	  an	  oven-­‐dried	  4	  mL	  conical	  vial	  was	  added	  bromobenzene	  (53	  µL,	  
0.5	  mmol),	  5-­‐amino-­‐2-­‐hydroxypyridine	   (66	  mg,	  0.6	  mmol),	   sodium	  tert-­‐butoxide	   (120	  mg,	  1.25	  mmol),	  
and	  BrettPhos	  palladacycle	  (0.8	  mg,	  0.001	  mmol).	   	  The	  vial	  was	  flushed	  with	  N2,	   then	  1	  mL	  anhydrous	  
1,4-­‐dioxane	  was	  added.	  	  The	  reaction	  was	  stirred	  at	  90	  C	  for	  3	  h.	  	  After	  cooling	  to	  RT,	  the	  reaction	  was	  
poured	  into	  water	  (30	  mL)	  and	  extracted	  with	  EtOAc	  (3	  x	  15	  mL).	  	  The	  organic	  extracts	  were	  dried	  over	  
MgSO4	   and	   the	   solvent	   was	   removed	   under	   reduced	   pressure.	   	   The	   crude	   product	   was	   dissolved	   in	  
DMSO	   (2	   mL)	   and	   purified	   by	   reverse-­‐phase	   HPLC	   using	   a	   5	   →	   95%	   acetonitrile	   in	   water	   gradient.	  	  
Lyophilization	  afforded	  9	  as	  a	  pale	  brown	  solid	  (30	  mg,	  32%	  yield).	  	  1H	  NMR	  (400	  MHz,	  DMSO-­‐d6)	  δ	  11.27	  
(s,	  1H),	  7.41	  (s,	  1H),	  7.34	  (dd,	  J	  =	  9.6,	  3.0	  Hz,	  1H),	  7.19	  –	  7.07	  (m,	  3H),	  6.71	  –	  6.61	  (m,	  3H),	  6.36	  (dd,	  J	  =	  
9.5,	   0.7	   Hz,	   1H).	   	   13C	   NMR	   (125	   MHz,	   DMSO-­‐d6)	   δ	   159.89,	   145.83,	   139.90,	   129.28,	   127.54,	   124.89,	  





2,3,5,6-­‐tetrafluoro-­‐4-­‐(o-­‐tolylamino)phenol	   (10).	   	   Compound	   10	   was	   prepared	   in	   a	  manner	   similar	   to	  
that	  described	  by	  Maiti	  and	  Buchwald.1	  To	  an	  oven-­‐dried	  4	  mL	  conical	  vial	  was	  added	  4-­‐bromo-­‐2,3,5,6-­‐
tetrafluorophenol	   (123	  mg,	   0.5	  mmol),	   o-­‐toluidine	   (64	   µL,	   0.6	  mmol),	   sodium	   tert-­‐butoxide	   (120	  mg,	  
1.25	  mmol),	  and	  BrettPhos	  palladacycle	  (0.8	  mg,	  0.001	  mmol).	  	  The	  vial	  was	  flushed	  with	  N2,	  then	  1	  mL	  
anhydrous	  1,4-­‐dioxane	  was	  added.	   	  The	  reaction	  was	  stirred	  at	  90	  C	  for	  18	  h.	   	  After	  cooling	  to	  RT,	  the	  
reaction	  was	  poured	   into	  a	  10%	  aqueous	  citric	  acid	  solution	  (15	  mL)	  and	  extracted	  with	  EtOAc	  (3	  x	  10	  
mL).	   	   The	   organic	   extracts	   were	   dried	   over	   MgSO4	   and	   the	   solvent	   was	   removed	   under	   reduced	  
pressure.	   	   Purification	   by	   automated	   silica	   gel	   chromatography	   using	   a	   6	   →	   50%	   EtOAc	   in	   hexanes	  
gradient	  afforded	  10	  as	  purple	  crystalline	  solid	  (80	  mg,	  59%	  yield).	   	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  7.20	  –	  
7.03	  (m,	  2H),	  6.86	  (td,	  J	  =	  7.4,	  1.2	  Hz,	  1H),	  6.55	  (dq,	  J	  =	  8.1,	  1.9	  Hz,	  1H),	  4.95	  (s,	  1H),	  2.31	  (s,	  3H).	  	  19F	  NMR	  
(400	  MHz,	  CDCl3)	  δ	   -­‐150.6	   (dd,	   J	  =	  22.6	  Hz,	  6.6	  Hz,	  2F),	   -­‐163.8	   (dd,	   J	  =	  22.6	  Hz,	  6.6	  Hz,	  2F).	   	  HRMS-­‐ESI	  







4-­‐([1,1'-­‐biphenyl]-­‐4-­‐ylamino)-­‐2,3,5,6-­‐tetrafluorophenol	  (11).	  	  Compound	  11	  was	  prepared	  in	  a	  manner	  
similar	   to	   that	   described	   by	  Maiti	   and	   Buchwald.1	   	   To	   an	   oven-­‐dried	   4	  mL	   conical	   vial	   was	   added	   4-­‐
bromo-­‐2,3,5,6-­‐tetrafluorophenol	   (123	   mg,	   0.5	   mmol),	   [1,1'-­‐biphenyl]-­‐4-­‐amine	   (102	   mg,	   0.6	   mmol),	  
sodium	  tert-­‐butoxide	  (120	  mg,	  1.25	  mmol),	  and	  BrettPhos	  palladacycle	  (0.8	  mg,	  0.001	  mmol).	  	  The	  vial	  
was	  flushed	  with	  N2,	  then	  1	  mL	  anhydrous	  1,4-­‐dioxane	  was	  added.	  	  The	  reaction	  was	  stirred	  at	  90	  C	  for	  
18	  h.	  	  After	  cooling	  to	  RT,	  the	  reaction	  was	  poured	  into	  a	  10%	  aqueous	  citric	  acid	  solution	  (15	  mL)	  and	  
extracted	  with	   EtOAc	   (3	   x	   10	  mL).	   	   The	   organic	   extracts	  were	   dried	   over	  MgSO4	   and	   the	   solvent	  was	  
removed	  under	  reduced	  pressure.	  	  Purification	  by	  automated	  silica	  gel	  chromatography	  using	  a	  6	  →	  50%	  
EtOAc	   in	   hexanes	   gradient	   afforded	   11	   as	   purple	   crystalline	   solid	   (105	  mg,	   63%	   yield).	   	   1H	  NMR	   (500	  
MHz,	  CDCl3)	  δ	  7.56	  –	  7.44	  (m,	  4H),	  7.43	  –	  7.35	  (m,	  2H),	  7.32	  –	  7.22	  (m,	  1H),	  6.84	  –	  6.77	  (m,	  2H),	  5.76	  (s,	  
1H),	  5.31	  (s,	  1H).	  	  19F	  NMR	  (400	  MHz,	  CDCl3)	  δ	  -­‐149.8	  (dd,	  J	  =	  23.2	  Hz,	  7.6	  Hz,	  2F),	  -­‐163.6	  (dd,	  J	  =	  23.2	  Hz,	  





2,3,5,6-­‐tetrafluoro-­‐4-­‐(naphthalen-­‐1-­‐ylamino)phenol	   (12).	   	   Compound	   12	   was	   prepared	   in	   a	   manner	  
similar	   to	   that	   described	   by	  Maiti	   and	   Buchwald.1	   	   To	   an	   oven-­‐dried	   4	  mL	   conical	   vial	   was	   added	   4-­‐
bromo-­‐2,3,5,6-­‐tetrafluorophenol	   (123	  mg,	  0.5	  mmol),	  naphthalen-­‐1-­‐amine	   (86	  mg,	  0.6	  mmol),	   sodium	  
tert-­‐butoxide	   (120	  mg,	   1.25	  mmol),	   and	   BrettPhos	   palladacycle	   (0.8	   mg,	   0.001	  mmol).	   	   The	   vial	   was	  
flushed	  with	  N2,	  then	  1	  mL	  anhydrous	  1,4-­‐dioxane	  was	  added.	  	  The	  reaction	  was	  stirred	  at	  90	  C	  for	  18	  h.	  	  
After	   cooling	   to	   RT,	   the	   reaction	   was	   poured	   into	   a	   10%	   aqueous	   citric	   acid	   solution	   (15	   mL)	   and	  
extracted	  with	   EtOAc	   (3	   x	   10	  mL).	   	   The	   organic	   extracts	  were	   dried	   over	  MgSO4	   and	   the	   solvent	  was	  
removed	  under	   reduced	  pressure.	   	   The	   crude	  product	  was	   dissolved	   in	  DMSO	   (2	  mL)	   and	  purified	  by	  
reverse-­‐phase	  HPLC	  using	  a	  5	  →	  95%	  acetonitrile	  in	  water	  gradient.	  	  Lyophilization	  afforded	  12	  as	  pale	  
purple	  solid	  (12	  mg,	  8%	  yield).	  	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  8.05	  (m,	  1H),	  7.89	  –	  7.80	  (m,	  1H),	  7.58	  –	  7.45	  
(m,	  3H),	  7.36	  –	  7.21	  (m,	  2H),	  6.73	  –	  6.65	  (m,	  1H),	  5.65	  (s,	  1H).	  	  19F	  NMR	  (400	  MHz,	  CDCl3)	  δ	  -­‐151.0	  (dd,	  J	  =	  
23.0	  Hz,	  5.8	  Hz,	  2F),	  -­‐163.5	  (dd,	  J	  =	  23.0	  Hz,	  5.8	  Hz,	  2F).	   	  HRMS-­‐ESI	  (m/z):	  [M+H]+	  calcd	  for	  C18H11F4NO,	  
























































































IV.	  	  GAS	  CHROMATOGRAPHY	  TRACES	  FOR	  COMPOUNDS	  7-­‐12	  
	  
General	   procedure.	   	   Gas	   chromatography	   was	   carried	   out	   using	   a	   Shimadzu	   GC	   2010	   containing	   a	  







Peak	   Retention	  Time	   Area	   %	  Area	  
1	   3.636	   513.3	   0.3	  







Peak	   Retention	  Time	   Area	   %	  Area	  
1	   7.399	   835686.0	   99.6	  
2	   12.400	   3050.1	   0.4	  



















Peak	   Retention	  Time	   Area	   %	  Area	  
1	   7.826	   3767.6	   0.8	  
2	   8.311	   18333.3	   4.0	  










Peak	   Retention	  Time	   Area	   %	  Area	  
1	   7.920	   1454029.6	   100.0	  
	  



















Peak	   Retention	  Time	   Area	   %	  Area	  
1	   6.927	   1071.8	   0.1	  
2	   9.672	   1024.6	   0.1	  









Peak	   Retention	  Time	   Area	   %	  Area	  
1	   10.945	   71352.0	   100.0	  
	  















V.	  	  BIOCHEMICAL	  SUBSTRATE	  IDENTIFICATION	  ASSAYS	  	  	  	  
	  
Single	  concentration	  screening	  of	  phenolic	  compounds	  as	  substrates	  for	  c-­‐Src.	  	  Substrate	  identification	  
assays	  were	  performed	  using	  an	  ADP-­‐Glo™	  assay	  kit	   (Promega).	   	  Compounds	  were	  solubilized	   in	  100%	  
DMSO	  to	  0.2M	  then	  subsequently	  diluted	  into	  ADP-­‐Glo	  Kinase	  buffer	  (40	  mM	  Tris	  pH	  7.5,	  20	  mM	  MgCl2,	  
0.1	  mg/ml	  bovine	  serum	  albumin)	  to	  a	  working	  stock	  concentration	  of	  167	  μM	  (1.7%	  DMSO).	  3	  μl	  of	  the	  
compound	  solution	  was	  added	  to	  the	  wells	  of	  a	  384-­‐well	  PerkinElmer	  Optiplate	  followed	  by	  the	  addition	  
of	   2	   μl	   of	   kinase/ATP	  mix	   (250	   nM	   c-­‐Src,	   250	   μM	  ATP	   in	   ADP-­‐Glo	   Kinase	   buffer).	   The	   plate	  was	   then	  
sealed	  and	  pulse-­‐spun	  in	  a	  table	  top	  centrifuge	  for	  10	  seconds	  to	  thoroughly	  mix	  the	  well	  contents.	  The	  
final	  concentrations	  in	  the	  well	  were:	  100	  μM	  compound	  (1.0%	  DMSO),	  100	  nM	  c-­‐Src,	  and	  100	  μM	  ATP.	  
The	  peptide	  substrate	  (Ac-­‐AIYAA-­‐NH2)	  was	  used	  as	  a	  control	  substrate	  to	  verify	  kinase	  activity.2	   	  Blank	  
wells	  containing	  the	  reaction	  mixture	  without	  substrate	  were	  included	  as	  well.	  The	  kinase	  reaction	  was	  
allowed	  to	  proceed	  at	  room	  temperature	   for	  30	  minutes	  after	  which	  the	  reaction	  was	  stopped	  by	  the	  
addition	   of	   5	   μl/well	   of	   ADP-­‐Glo	   Reagent	   (Promega).	   The	   contents	   were	   mixed	   by	   centrifugation	   as	  
above	   and	   an	   additional	   room	   temperature	   40	   minute	   incubation	   was	   followed	   per	   the	   Promega	  
protocol.	  10	  μl/well	  of	  Kinase	  Detection	  Reagent	  (Promega)	  was	  added	  to	  each	  well,	  the	  plate	  was	  spun	  
as	   described	   to	   mix	   the	   contents,	   and	   an	   additional	   30	   minute	   room	   temperature	   incubation	   was	  
performed	  per	   the	  Promega	  protocol.	   Luminescence	  was	   read	   in	   a	  Biotek	   Synergy	   4	  multimode	  plate	  
reader	   and	   the	   %	   ADP	   formed	   in	   the	   well	   was	   calculated	   against	   a	   standard	   curve	   using	   a	   ratio	   of	  







Table	  S1.	  	  Average	  percent	  ADP	  generated	  by	  c-­‐Src	  after	  30	  minutes	  in	  the	  presence	  of	  small	  molecule	  
phenols.	  	  	  

















4.6	  ±	  4.8	  (n=4)	  
P-­‐S4	  
	  




4.3	  ±	  2.5	  (n=3)	  
P-­‐S6	  
	  













2.5	  ±	  5.5	  (n=4)	  
P-­‐S10	  
	  
1.4	  ±	  2.6	  (n=2)	  
P-­‐S11	  
	  
1.3	  ±	  1.7	  (n=2)	  
P-­‐S12	  
	  
1.0	  ±	  4.1	  (n=3)	  
P-­‐S13	  
	  





0.8	  ±	  2.3	  (n=2)	  
P-­‐S15	  
	  
0.4	  ±	  1.5	  (n=2)	  
P-­‐S16	  
	  
0.1	  ±	  0.7	  (n=2)	  
P-­‐S17	  
	  
0.0	  ±	  0.4	  (n=2)	  
P-­‐S18	  
	  
-­‐0.2	  ±	  0.2	  (n=2)	  
P-­‐S19	  
	  
-­‐0.2	  ±	  0.6	  (n=2)	  
P-­‐S20	  
	  





-­‐0.2	  ±	  0.2	  (n=2)	  
P-­‐S22	  
	  
-­‐0.3	  ±	  0.3	  (n=2)	  
P-­‐S23	  
	  
-­‐0.4	  ±	  1.5	  (n=2)	  
P-­‐S24	  
	  
-­‐0.4	  ±	  1.0	  (n=2)	  
P-­‐S25	  
	  
-­‐0.5	  ±	  1.0	  (n=2)	  
P-­‐S26	  
	  
-­‐0.6	  ±	  0.7	  (n=2)	  
P-­‐S27	  
	  





-­‐0.7	  ±	  0.2	  (n=2)	  
P-­‐S29	  
	  
-­‐0.8	  ±	  1.1	  (n=2)	  
P-­‐S30	  
	  
-­‐0.9	  ±	  0.4	  (n=2)	  
P-­‐S31	  
	  
-­‐0.9	  ±	  0.1	  (n=2)	  
P-­‐S32	  
	  
-­‐0.9	  ±	  0.5	  (n=2)	  
P-­‐S33	  
	  
-­‐1.0	  ±	  0.4	  (n=2)	  
P-­‐S34	  
	  





-­‐1.0	  ±	  0.3	  (n=2)	  
P-­‐S36	  
	  
-­‐1.0	  ±	  1.0	  (n=2)	  
P-­‐S37	  
	  
-­‐1.1	  ±	  0.3	  (n=2)	  
P-­‐S38	  
	  
-­‐1.1	  ±	  0.5	  (n=2)	  
P-­‐S39	  
	  
-­‐1.2	  ±	  1.3	  (n=2)	  
P-­‐S40	  
	  
-­‐1.2	  ±	  1.3	  (n=2)	  
P-­‐S41	  
	  





-­‐1.3	  ±	  0.2	  (n=2)	  
P-­‐S43	  
	  
-­‐1.3	  ±	  1.3	  (n=2)	  
P-­‐S44	  
	  
-­‐1.3	  ±	  0.7	  (n=2)	  
P-­‐S45	  
	  
-­‐1.3	  ±	  1.5	  (n=2)	  
P-­‐S46	  
	  
-­‐1.4	  ±	  0.3	  (n=2)	  
P-­‐S47	  
	  
-­‐1.4	  ±	  0.0	  (n=2)	  
P-­‐S48	  
	  





-­‐1.4	  ±	  0.9	  (n=2)	  
P-­‐S50	  
	  
-­‐1.5	  ±	  0.2	  (n=2)	  
P-­‐S51	  
	  
-­‐1.6	  ±	  0.3	  (n=4)	  
P-­‐S52	  
	  
-­‐1.6	  ±	  1.1	  (n=2)	  
P-­‐S53	  
	  
-­‐1.7	  ±	  0.7	  (n=2)	  
P-­‐S54	  
	  
-­‐1.9	  ±	  0.2	  (n=2)	  
P-­‐S55	  
	  





-­‐1.9	  ±	  0.3	  (n=2)	  
P-­‐S57	  
	  
-­‐1.9	  ±	  1.3	  (n=2)	  
P-­‐S58	  
	  
-­‐2.0	  ±	  1.0	  (n=2)	  
P-­‐S59	  
	  
-­‐2.0	  ±	  1.2	  (n=2)	  
P-­‐S60	  
	  
-­‐2.1	  ±	  0.8	  (n=2)	  
P-­‐S61	  
	  
-­‐2.2	  ±	  0.2	  (n=2)	  
P-­‐S62	  
	  





-­‐2.3	  ±	  0.3	  (n=2)	  
P-­‐S64	  
	  
-­‐2.3	  ±	  0.8	  (n=2)	  
P-­‐S65	  
	  
-­‐2.4	  ±	  0.2	  (n=2)	  
P-­‐S66	  
	  
-­‐2.5	  ±	  0.3	  (n=2)	  
P-­‐S67	  
	  
-­‐2.5	  ±	  0.4	  (n=2)	  
P-­‐S68	  
	  
-­‐2.6	  ±	  0.0	  (n=2)	  
P-­‐S69	  
	  





-­‐2.6	  ±	  0.6	  (n=2)	  
P-­‐S71	  
	  
-­‐2.7	  ±	  0.2	  (n=2)	  
P-­‐S72	  
	  
-­‐2.7	  ±	  0.0	  (n=2)	  
P-­‐S73	  
	  
-­‐2.7	  ±	  0.7	  (n=2)	  
P-­‐S74	  
	  
-­‐2.8	  ±	  0.6	  (n=2)	  
P-­‐S75	  
	  
-­‐2.8	  ±	  0.1	  (n=2)	  
P-­‐S76	  
	  





-­‐2.8	  ±	  0.5	  (n=2)	  
P-­‐S78	  
	  
-­‐2.8	  ±	  0.6	  (n=2)	  
P-­‐S79	  
	  
-­‐2.9	  ±	  0.7	  (n=2)	  
P-­‐S80	  
	  
-­‐2.9	  ±	  1.8	  (n=2)	  
P-­‐S81	  
	  
-­‐2.9	  ±	  0.6	  (n=2)	  
P-­‐S82	  
	  
-­‐3.0	  ±	  1.5	  (n=2)	  
P-­‐S83	  
	  





-­‐3.1	  ±	  0.3	  (n=2)	  
P-­‐S85	  
	  
-­‐3.1	  ±	  0.3	  (n=2)	  
P-­‐S86	  
	  
-­‐3.1	  ±	  0.2	  (n=2)	  
P-­‐S87	  
	  
-­‐3.3	  ±	  0.9	  (n=2)	  
P-­‐S88	  
	  
-­‐3.3	  ±	  0.8	  (n=2)	  
	  
	   	  
S32	  
	  
KM	   determination	   for	   phenolic	   c-­‐Src	   substrates.	   	   The	   KM	   values	   for	   the	   phenolic	   substrates	   were	  
determined	   using	   an	   ADP-­‐Glo™	   assay	   kit	   (Promega).	   The	   compounds	   were	   supplied	   as	   100%	   DMSO	  
solutions	   at	   200	  mM	   and	  were	   diluted	   to	   2.5	  mM	   into	   ADP-­‐Glo	   buffer	   (40	  mM	   Tris,	   pH	   7.5,	   20	  mM	  
MgCl2,	  0.1	  mg/ml	  BSA,	  0.1	  mM	  Na3VO4,	  0.01%	  Triton	  X-­‐100).	  1:1	  dilutions	  were	  done	  in	  ADP-­‐Glo	  buffer	  
containing	  1.25%	  DMSO	  and	  2	  μl	  of	  the	  solutions	  (in	  triplicate)	  were	  then	  added	  to	  wells	  of	  a	  384-­‐well	  
PerkinElmer	  Optiplate.	   The	   kinase	   and	  ATP	   solution	  was	   prepared	   in	  ADP-­‐Glo	   buffer	   to	   2.5X	   the	   final	  
concentrations	  desired	  in	  the	  assay	  and	  3	  μl	  was	  added	  to	  the	  wells	  containing	  the	  compound.	  The	  final	  
concentrations	  used	  in	  the	  assay	  were:	  ATP	  =	  100	  μM,	  Src	  and	  Hck	  =	  30	  nM,	  Abl	  =	  150	  nM.	  The	  solutions	  
were	   mixed	   in	   the	   plate	   by	   a	   brief	   centrifugation	   and	   allowed	   to	   incubate	   for	   30	   minutes	   at	   room	  
temperature.	  5	  μl	  of	  ADP-­‐Glo	  Reagent	  was	  added	   to	  each	  well	   and	  mixed	  by	  a	  brief	   centrifugation	   to	  
terminate	   the	   kinase	   reaction.	   The	   plate	   was	   then	   incubated	   an	   additional	   40	   minutes	   at	   room	  
temperature.	  The	  luciferase	  signal	  was	  generated	  by	  adding	  10	  μl	  per	  well	  of	  Kinase	  Detection	  Reagent	  
and	  mixing	  by	  a	  brief	  centrifugation	  and	  incubation	  for	  30	  minutes	  at	  room	  temperature.	  Luminescence	  
was	  measured	  in	  a	  Biotek	  synergy	  4	  multimode	  plate	  reader.	  ATP	  conversion	  was	  determined	  against	  a	  
standard	  curve	  of	  ATP/ADP	  using	  the	  ADP-­‐Glo	  workup	  conditions	  listed	  above.	  	  
	  
	  
Table	  S2.	  KM	  values	  for	  small	  molecule	  phenols	  with	  c-­‐Src,	  Hck,	  and	  c-­‐Abl.	  
Name	   Structure	   KM	  c-­‐Src	  
Vmax	  c-­‐Src	  

























522	  µM	   19	   169	  µM	   >1	  mM	  
P-­‐S6	  
	  
>10	  mM	   ND	   NDa	   NDa	  
P-­‐S7	  
	  








33	  µM	   14	   NDa	   NDa	  
12	  
	  
>1	  mM	   0	   NDa	   NDa	  
aKM	  value	  was	  not	  determined.	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Analytical	   data	   for	   KM	   determinations.	   	   The	   KM	   curve	   for	   substrates	   P-­‐S1	   –	   P-­‐S9	   with	   c-­‐Src	   kinase	  
domain	   is	   shown	   below.	   	   Inhibitor	  12	   was	   also	   evaluated	   as	   a	   c-­‐Src	   substrate	   and	   the	   data	   is	   shown	  
below.	  	  KM	  curves	  for	  P-­‐S1,	  P-­‐S2,	  P-­‐S5,	  and	  P-­‐S8	  with	  Hck	  kinase	  domain	  are	  also	  shown.	  	  Each	  data	  point	  
was	  determined	  in	  triplicate	  and	  is	  shown	  as	  the	  mean	  ±	  standard	  error.	   	  Curve	  fitting	  was	  done	  using	  



































	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  
P-S3 Src
















	   	  
	  
P-S5 Src














	  	  	  	  	  	  	  	  	  	  	  	  	  
P-S4-Src

































	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
P-S7 Src
































     KM 119.7
	  	  	  	  	  	  	  	  	  	  
P-S9 Src



















inhibitor 12 - Src








































     KM 124.3
	  	  	  	  	  	  	  	  	  	  	  	  	  
P-S2 Hck

































     KM 169.3
	  	  	  	  	  	  	  	  	  	  	  	  	  
P-S8 Hck











     KM 136.8
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Analytical	  data	  for	  confirmation	  of	  c-­‐Src	  mediated	  phosphorylation.	  	  The	  phosphorylation	  of	  phenol	  P-­‐
S2	  by	  c-­‐Src	  was	  monitored	  by	  analytical	  reverse	  phase	  HPLC	  (Zorbax	  Eclipse	  Plus	  C18	  	  4.6	  x	  75	  mm,	  3.5	  
µm	  column)	  using	  an	  acetonitrile	   in	  water	   (+0.1%	  TFA)	  gradient	   (5%	  ACN	  for	  3	  min,	   then	  5→70%	  ACN	  
over	  10	  min).	  	  The	  enzymatic	  reaction	  had	  a	  final	  concentration	  200	  µM	  P-­‐S2,	  200	  µM	  ATP,	  6 µM	  c-­‐Src,	  
100	  mM	  Tris	  buffer	  (pH	  8),	  and	  10	  mM	  MgCl2.	  	  The	  phosphate	  P-­‐S2-­‐phos	  was	  prepared	  as	  described	  by	  
Soellner	  et	  al	  and	  used	  as	  a	  standard.3	  
	  
	   	   	   	  
	  
	  
200	  µM	  P-­‐S2	  
	  
	  





















60	  min	  incubation:	  200	  µM	  P-­‐S2,	  200	  µM	  ATP,	  and	  6	  µM	  c-­‐Src	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VI.	  	  BIOCHEMICAL	  CHARACTERIZATIONS	  OF	  COMPOUNDS	  7-­‐12	  
	  
General	  procedures.	  	  Black,	  opaque-­‐bottom	  96	  well	  plates	  were	  purchased	  from	  Nunc.	  	  c-­‐Src,	  c-­‐Abl,	  and	  
Hck	  were	  expressed	  in	  E.	  coli	  using	  previously	  published	  procedures.4	  	  Chicken	  c-­‐Src	  numbering	  is	  used	  
unless	  otherwise	  noted.	  	  Blk,	  Fgr,	  Frk,	  Fyn	  A,	  Lck,	  and	  Lyn	  A	  were	  purchased	  from	  SignalChem.	  	  Data	  was	  
obtained	   using	   a	   Molecular	   Devices	   SpectraMax	   M5	   plate	   reader.	   	   Curve	   fitting	   was	   done	   using	  
Graphpad	  Prism	  4	  software.	  
	  
General	   procedure	   for	   determination	   of	   inhibitor	   Ki.	   	   A	   continuous	   fluorescence	   assay	   was	   used	   to	  
determine	  Ki.5	  Reaction	  volumes	  of	  100	  µL	  were	  used	   in	  96-­‐well	  plates.	  85	  µL	  of	  enzyme	  in	  buffer	  mix	  
was	  added	  to	  each	  well	  followed	  by	  2.5	  µL	  of	  the	  appropriate	  inhibitor	  dilution	  (typically	  80,	  40,	  20,	  10,	  
5,	  2.5,	  1.25,	  0.625	  mM	  in	  DMSO)	  and	  2.5	  µL	  of	  a	  substrate	  peptide	  solution	  (“compound	  3”	  as	  described	  
in	  Wang	   et	   al.,	   typically	   1.8	  mM	   in	   DMSO).	   The	   reaction	  was	   initiated	  with	   10	   µL	   of	   ATP	   (10	  mM	   in	  
water),	   and	   reaction	   progress	   was	   immediately	   monitored	   at	   405	   nm	   (ex.	   340	   nm)	   for	   10	   minutes.	  	  
Reactions	  had	   final	   concentrations	  of	   1	  mM	  ATP,	   100	  µM	  Na3VO4,	   100mM	  Tris	   buffer	   (pH	  8),	   10	  mM	  
MgCl2,	  and	  0.01%	  Triton	  X-­‐100.	  Final	  concentrations	  of	  enzyme	  and	  “substrate	  3”	  for	  each	  kinase	  are	  as	  
follows:	  c-­‐Src	  kinase	  domain,	  3	  domain	  (3D)	  c-­‐Src,	  phosphorylated	  (pY416)	  c-­‐Src	  kinase	  domain,	  double	  
mutant	  R388A/A390R	  c-­‐Src	  kinase	  domain,	  Hck	  kinase	  domain	  assays,	  and	  Yes	  kinase	  domain	  reactions	  
had	  a	   final	  concentration	  of	  30	  nM	  enzyme	  and	  45	  µM	  peptide	  substrate.	  T338M	  c-­‐Src	  kinase	  domain	  
reactions	  had	  a	  final	  concentration	  of	  30	  nM	  enzyme	  and	  20	  µM	  peptide	  substrate.	  c-­‐Abl	  kinase	  domain	  
reactions	  had	  a	  final	  concentration	  of	  120	  nM	  enzyme	  and	  120	  µM	  peptide	  substrate.	  	  3D	  Blk	  reactions	  
had	  a	  final	  concentration	  of	  30	  nM	  enzyme	  and	  85	  µM	  peptide	  substrate.	  	  3D	  Fgr	  reactions	  had	  a	  final	  
concentration	   of	   30	   nM	   enzyme	   and	   54	   µM	   peptide	   substrate.	   	   3D	   Frk	   reactions	   had	   a	   final	  
concentration	   of	   30	   nM	   enzyme	   and	   165	   µM	   peptide	   substrate.	   	   3D	   Fyn	   A	   reactions	   had	   a	   final	  
concentration	   of	   30	   nM	   enzyme	   and	   69	   µM	   peptide	   substrate.	   	   3D	   Lck	   reactions	   had	   a	   final	  
concentration	   of	   30	   nM	   enzyme	   and	   96	   µM	   peptide	   substrate.	   	   3D	   Lyn	   A	   reactions	   had	   a	   final	  
concentration	  of	  30	  nM	  enzyme	  and	  140	  µM	  peptide	  substrate.	  	  The	  initial	  rate	  data	  collected	  was	  used	  
for	   determination	   of	   Ki	   values.	   	   For	   Ki	   determination,	   the	   kinetic	   values	   were	   obtained	   directly	   from	  
nonlinear	   regression	   of	   substrate-­‐velocity	   curves	   in	   the	   presence	   of	   various	   concentrations	   of	   the	  
inhibitor.	  	  	  The	  KM	  values	  used	  for	  “substrate	  3”	  were	  obtained	  from	  Wang	  et	  al	  or	  were	  determined	  as	  
described	  below	  (see	  “General	  procedure	  for	  determination	  of	  “substrate	  3”	  KM”).5	  
	  
For	   biochemical	   evaluation	   of	   PP2,	   the	   protocol	   above	   was	   followed	   with	   modifications	   to	   the	   ATP	  
concentration.	  	  c-­‐Src,	  Blk,	  Fgr,	  Frk,	  Fyn	  A,	  Lck,	  and	  Lyn	  A	  reactions	  had	  a	  final	  concentration	  of	  300	  µM	  
ATP.	   	   c-­‐Abl	  and	  Hck	   reactions	  had	  a	   final	   concentration	  of	  100	  µM	  ATP,	  and	  Yes	   reactions	  had	  a	   final	  
concentration	  of	   500	  µM	  ATP.	   	   The	  KM	  values	  used	   for	  ATP	  were	  obtained	   from	  Carna	  Biosciences	  or	  
were	  determined	  as	  described	  below	  (see	  “General	  procedure	  for	  determination	  of	  ATP	  KM”).6	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Focused	   library.	   	   A	   focused	   library	  of	   10	   inhibitors	  was	  prepared	  and	  evaluated	  using	   the	   continuous	  
fluorescence	   assay	   described	   above.	   	   Each	   inhibitor	   Ki	   value	   was	   determined	   using	   at	   least	   3	  
independent	  experiments	  which	  were	  averaged	  to	  give	  an	  average	  Ki	  value	  ±	  standard	  deviation.	  
	  
	  
Table	  S3.	  c-­‐Src	  Ki	  values	  for	  a	  focused	  library	  of	  analogues	  of	  compound	  7.	  
Name	   Structure	   c-­‐Src	  Ki	  (µM)	  
S4	  
	  
549	  ±	  57	  
S5	  
 
406	  ±	  67	  
10	  
 
127	  ±	  11	  
S6	  
 
229	  ±	  49	  
S7	  
 





443	  ±	  13	  
S9	  
 
318	  ±	  16	  
11	  
 
80	  ±	  6	  
S10	  
 
257	  ±	  8	  
12	  
 
16	  ±	  1	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Analytical	   data	   for	   Ki	   determinations.	   	   Each	   inhibitor	   Ki	   value	   was	   determined	   using	   at	   least	   3	  
independent	  experiments	  (unless	  otherwise	  noted)	  which	  were	  averaged	  to	  give	  an	  average	  Ki	  value	  ±	  
standard	   deviation.	   	   A	   representative	   curve	   is	   shown	   for	   inhibitors	   7-­‐12	   and	   PP2	   with	   c-­‐Src	   kinase	  
domain,	  Hck	  kinase	  domain,	  and	  c-­‐Abl	  kinase	  domain.	  For	  inhibitor	  12	  additional	  representative	  curves	  
are	   shown	   for	   Yes	   kinase	   domain,	   3	   domain	   (3D)	   c-­‐Src,	   phosphorylated	   (pY416)	   c-­‐Src	   kinase	   domain,	  
T338M	  c-­‐Src	  kinase	  domain,	  double	  mutant	  R388A/A390R	  c-­‐Src	  kinase	  domain,	  3D	  Blk,	  3D	  Fgr,	  3D	  Frk,	  
3D	   Fyn	  A,	   3D	   Lck,	   and	   3D	   Lyn	  A.	   	   For	   PP2,	   additional	   representative	   curves	   are	   shown	   for	   Yes	   kinase	  




	   c-­‐Src	  Ki	  =	  257	  ±	  28	  µM	   	   	   	   	   Hck	  Ki	  =	  1015	  ±	  165	  µM	  
	  
















	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  






















c-­‐Abl	  Ki	  >1170	  µM	  























c-­‐Src	  Ki	  =	  478	  ±	  82	  µM	   	   	   	   	   Hck	  Ki	  =	  517	  ±	  32	  µM	  
	  
















	   	  




















c-­‐Abl	  Ki	  >1170	  µM	  

































c-­‐Src	  Ki	  =	  552	  ±	  9	  µM	   	   	   	   	   Hck	  Ki	  =	  318	  ±	  17	  µM	   	  
	   	  








































c-­‐Abl	  Ki	  =	  1046	  ±	  176	  µM	   	   	   	   	   	  



























	   	   c-­‐Src	  Ki	  =	  127	  ±	  11	  µM	   	   	   	   	   Hck	  Ki	  >1080	  µM	   	   	  	  
















	   	  


















	   	   	   	   	  
	   	   	   	   	  
	  
	   	   c-­‐Abl	  Ki	  >1170	  µM	   	   	   	   	   	  	  


























c-­‐Src	  Ki	  =	  80	  ±	  6	  µM	   	   	   	   	   Hck	  Ki	  =	  149	  ±	  6	  µM	  	  
















	   	  





















c-­‐Abl	  Ki	  =	  549	  ±	  138	  µM	  




























c-­‐Src	  Ki	  =	  16	  ±	  1	  µM	   	   	   	   	   Hck	  Ki	  =	  325	  ±	  30	  µM	  






































c-­‐Abl	  Ki	  =	  	  1067	  ±	  385	  µM	   	   	   pY416	  c-­‐Src	  Ki	  =	  73	  ±	  9	  µM	   	  


















	   	  























	   T338M	  c-­‐Src	  Ki	  =	  75	  ±	  15	  µM	   	   	   	   R388A/A390R	  c-­‐Src	  Ki	  =	  184	  ±	  53	  µM	   	  
















	   	  





















Yes	  Ki	  =	  82	  ±	  16	  µM	  





















Blk	  Ki	  =	  52	  µM	  (n	  =	  1)	   	   	   	   	   Fgr	  Ki	  =	  51	  µM	  (n	  =	  1)	  















	   	  























Frk	  Ki	  =	  83	  µM	  (n	  =	  1)	   	   	   	   	   Fyn	  A	  Ki	  =	  61	  µM	  (n	  =	  1)	  









































Lck	  Ki	  =	  63	  µM	  (n	  =	  1)	   	   	   	   	   Lyn	  A	  Ki	  =	  60	  µM	  (n	  =	  1)	  




































	   	   	  







c-­‐Src	  Ki	  =	  45	  ±	  1	  nM	   	   	   	   	   Hck	  Ki	  =	  88	  ±	  5	  nM	  
	  

















	   	  





















c-­‐Abl	  Ki	  =	  	  387	  ±	  17	  nM	   	   	   	   	   Yes	  Ki	  =	  46	  ±	  11	  nM	  
	  
















	   	  























Blk	  Ki	  =	  67	  nM	  (n	  =	  1)	   	   	   	   	   Fgr	  Ki	  =	  25	  nM	  (n	  =	  1)	  

















	   	  




















Frk	  Ki	  =	  20	  nM	  (n	  =	  1)	   	   	   	   	   Fyn	  A	  Ki	  =	  20	  nM	  (n	  =	  1)	  




































Lck	  Ki	  =	  9	  nM	  (n	  =	  1)	   	   	   	   	   Lyn	  A	  Ki	  =	  16	  nM	  (n	  =	  1)	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General	  procedure	  for	  determination	  of	  “substrate	  3”	  KM.	   	  A	  continuous	  fluorescence	  assay	  was	  used	  
to	  determine	  KM	  for	  “substrate	  3”	  described	  in	  Wang	  et	  al.5	  Reaction	  volumes	  of	  100	  µL	  were	  used	  in	  96-­‐
well	  plates.	  85	  µL	  of	  enzyme	  in	  buffer	  mix	  was	  added	  to	  each	  well	  followed	  by	  2.5	  µL	  of	  the	  appropriate	  
dilution	  of	  “substrate	  3”	  (typically	  20,	  10,	  5,	  2.5,	  1.25,	  0.625,	  0.31,	  0.16,	  0.078,	  and	  0	  mM	  in	  DMSO)	  and	  
2.5	  µL	  of	  DMSO.	  The	  reaction	  was	  initiated	  with	  10	  µL	  of	  ATP	  (10	  mM	  in	  water),	  and	  reaction	  progress	  
was	  immediately	  monitored	  at	  405	  nm	  (ex.	  340	  nm)	  for	  10	  minutes.	  Reactions	  had	  final	  concentrations	  
of	  1	  mM	  ATP,	  100	  µM	  Na3VO4,	  100mM	  Tris	  buffer	  (pH	  8),	  10	  mM	  MgCl2,	  and	  0.01%	  Triton	  X-­‐100.	  c-­‐Src,	  
Hck,	  Yes,	  Blk,	  and	  Frk	  reactions	  had	  a	  final	  concentration	  of	  30	  nM	  enzyme,	  and	  c-­‐Abl	  reactions	  had	  a	  
final	  concentration	  of	  120	  nM	  enzyme.	  The	  initial	  rate	  data	  collected	  was	  used	  for	  determination	  of	  KM	  
values.	   For	   KM	   determination,	   the	   kinetic	   values	   were	   obtained	   directly	   from	   nonlinear	   regression	   of	  
substrate-­‐velocity	  curves.	  
	  
General	   procedure	   for	   determination	   of	   ATP	   KM.	   	   A	   continuous	   fluorescence	   assay	   was	   used	   to	  
determine	  KM	  for	  ATP	  described	  in	  Wang	  et	  al.5	  Reaction	  volumes	  of	  100	  µL	  were	  used	  in	  96-­‐well	  plates.	  
85	  µL	  of	  enzyme	  in	  buffer	  mix	  was	  added	  to	  each	  well	   followed	  by	  2.5	  µL	  of	  “substrate	  3”	  (1.8	  mM	  in	  
DMSO)	  and	  2.5	  µL	  of	  DMSO.	  The	  reaction	  was	  initiated	  with	  10	  µL	  of	  ATP	  (typically	  10,	  5,	  2.5,	  1.25,	  0.63,	  
0.31,	  0.16,	  0.078,	  0.039,	  and	  0	  mM	  in	  water),	  and	  reaction	  progress	  was	  immediately	  monitored	  at	  405	  
nm	   (ex.	   340	  nm)	   for	   10	  minutes.	   Reactions	  had	   final	   concentrations	  of	   45	  µM	  “substrate	   3”,	   100	  µM	  
Na3VO4,	  100mM	  Tris	  buffer	  (pH	  8),	  10	  mM	  MgCl2,	  and	  0.01%	  Triton	  X-­‐100.	  c-­‐Src,	  Hck,	  and	  Yes	  reactions	  
had	  a	   final	   concentration	  of	   30	  nM	  enzyme,	   and	   c-­‐Abl	   reactions	  had	  a	   final	   concentration	  of	   120	  nM	  
enzyme.	  The	  initial	  rate	  data	  collected	  was	  used	  for	  determination	  of	  KM	  values.	  For	  KM	  determination,	  
the	  kinetic	  values	  were	  obtained	  directly	  from	  nonlinear	  regression	  of	  substrate-­‐velocity	  curves.	  
	  
Analytical	  data	  for	  KM	  determinations.	  	  The	  “substrate	  3”	  and	  ATP	  KM	  values	  were	  determined	  using	  at	  
least	  3	  independent	  experiments	  which	  were	  averaged	  to	  give	  an	  average	  KM	  value	  ±	  standard	  deviation.	  	  
A	   representative	   curve	   for	   “substrate	   3”	   is	   shown	   for	   c-­‐Src	   kinase	   domain,	   3-­‐domain	   (3D)	   c-­‐Src,	  
phosphorylated	  (pY416)	  c-­‐Src	  kinase	  domain,	  T338M	  c-­‐Src	  kinase	  domain,	  double	  mutant	  R388A/A390R	  
c-­‐Src	  kinase	  domain,	  Hck	  kinase	  domain,	  Yes	  kinase	  domain,	  3D	  Blk,	  3D	  Frk,	  and	  c-­‐Abl	  kinase	  domain.	  	  A	  
representative	   curve	   for	   ATP	   is	   shown	  with	   c-­‐Abl	   kinase	   domain,	   Hck	   kinase	   domain,	   and	   Yes	   kinase	  
domain.	   	  For	  analytical	  data	  for	  ATP	  with	  c-­‐Src	  kinase	  domain	  see	  Kwarcinski	  et	  al.7	   	  For	  “substrate	  3”	  
with	  Fgr,	  Fyn	  A,	  Lck,	  and	  Lyn	  A	  the	  KM	  values	  reported	  in	  Wang	  et	  al.	  were	  used.5	  	  For	  ATP	  with	  Blk,	  Fgr,	  
Frk,	  Fyn	  A,	  Lck,	  and	  Lyn	  A	  the	  KM	  values	  reported	  by	  Carna	  Biosciences	  were	  used.6	  
	  
	  
“substrate	  3”	  c-­‐Src	  KM	  =	  61	  ±	  4	  µM	   	   	   “substrate	  3”	  Hck	  KM	  =	  53	  ±	  2	  µM	  
	   	  




























	  	  	  	  	  	  “substrate	  3”	  c-­‐Abl	  KM	  =	  168	  ±	  19	  µM	   	  	  	  	  	  	  	  	  	  	  	  “substrate	  3”	  R388A/A390R	  c-­‐Src	  KM	  =	  70	  ±	  17	  µM	  	  































	   “substrate	  3”	  T338M	  c-­‐Src	  KM	  =	  26	  ±	  8	  µM	   	   “substrate	  3”	  3D	  c-­‐Src	  KM	  =	  64	  ±	  4	  µM	  
































“substrate	  3”	  pY416	  Src	  KM	  =	  43	  ±	  3	  µM	   	   	   “substrate	  3”	  Yes	  KM	  =	  62	  ±	  6	  µM	  
































	   “substrate	  3”	  Blk	  KM	  =	  85	  µM	  (n	  =	  1)	   	   	   “substrate	  3”	  Frk	  KM	  =	  165	  µM	  (n	  =	  1)	  











	   	  















	   ATP	  c-­‐Abl	  KM	  =	  37	  ±	  6	  µM	   	   	   	   ATP	  Hck	  KM	  =	  50	  ±	  3	  µM	  











	   	  















	   ATP	  Yes	  KM	  =	  105	  ±	  21	  µM	  
	  
	   	  

















Changes	   in	   IC50	   for	   compounds	   7-­‐9	   and	   12	   at	   variable	   substrate	   and	   ATP	   concentrations.	   	   The	  
continuous	  fluorescence	  assay	  described	  previously	  was	  used	  to	  determine	   IC50	  for	   inhibitors	  at	  higher	  
“substrate	   3”	   concentration	   and	   at	   lower	   ATP	   concentration	   with	   c-­‐Src.5	   	   For	   higher	   “substrate	   3”	  
conditions	  the	  reactions	  had	  final	  concentrations	  of	  30	  nM	  c-­‐Src,	  500	  µM	  “substrate	  3”,	  1	  mM	  ATP,	  100	  
µM	  Na3VO4,	  100mM	  Tris	  buffer	  (pH	  8),	  10	  mM	  MgCl2,	  and	  0.01%	  Triton	  X-­‐100.	  	  For	  lower	  ATP	  conditions	  
the	   reactions	   had	   final	   concentrations	   of	   30	   nM	   c-­‐Src,	   45	   µM	   “substrate	   3”,	   100	   µM	   ATP,	   100	   µM	  
Na3VO4,	  100mM	  Tris	  buffer	  (pH	  8),	  10	  mM	  MgCl2,	  and	  0.01%	  Triton	  X-­‐100.	  The	  initial	  rate	  data	  collected	  
was	  used	   for	  determination	  of	   IC50	   values,	  which	  were	  obtained	  directly	   from	  nonlinear	   regression	  of	  
substrate-­‐velocity	  curves	   in	  the	  presence	  of	  various	  concentrations	  of	  the	   inhibitor.	   	  The	   IC50	  value	  for	  
inhibitors	  under	  each	  set	  of	  conditions	  was	  determined	  using	  at	  least	  3	  independent	  experiments	  which	  
were	  averaged	  to	  give	  an	  average	  IC50	  ±	  standard	  deviation.	  	  Representative	  curves	  for	  compound	  12	  are	  
shown	  for	  each	  set	  of	  conditions.	  
	  
	  
Table	  S4.	  c-­‐Src	  IC50	  values	  under	  standard	  and	  high	  “substrate	  3”	  conditions.	  
Compound	   IC50	  under	  standard	  conditions	   IC50	  under	  high	  substrate	  conditions	  
7	   436	  ±	  60	  µM	   >2000	  µM	  
8	   830	  ±	  143	  µM	   1520	  ±	  440	  µM	  
9	   958	  ±	  16	  µM	   1742	  ±	  614	  µM	  





	  	  	  	  	  	  	  	  	  12	  with	  high	  “substrate	  3”	  conditions	  
	  	  	  	  	  	  	  	  IC50	  =	  557	  ±	  149	  µM	   	   	   	  	  	  	  	  	  	  	  12	  with	  low	  ATP	  conditions	  IC50	  =	  44	  ±	  4	  µM	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General	   procedure	   for	   Lineweaver-­‐Burk	   analysis	   of	   compound	   12.	   	  A	   continuous	   fluorescence	   assay	  
was	  used	  to	  determine	  initial	  velocities	  for	  ATP	  and	  “substrate	  3”	  described	  in	  Wang	  et	  al	  with	  c-­‐Src	  in	  
the	  presence	  of	  compound	  12.5	  	  
	  
For	  “substrate	  3”,	  reaction	  volumes	  of	  100	  µL	  were	  used	  in	  96-­‐well	  plates.	  85	  µL	  of	  enzyme	  in	  buffer	  mix	  
was	  added	  to	  each	  well	  followed	  by	  2.5	  µL	  of	  the	  appropriate	  dilution	  of	  “substrate	  3”	  (typically	  20,	  10,	  
5,	  2.5,	  1.25,	  0.625,	  0.31,	  0.16,	  0.078,	  and	  0	  mM	  in	  DMSO)	  and	  2.5	  µL	  of	  compound	  12	   (0.4,	  1.2,	  or	  2.4	  
mM	  in	  DMSO).	  The	  reaction	  was	  initiated	  with	  10	  µL	  of	  ATP	  (5	  mM	  in	  water),	  and	  reaction	  progress	  was	  
immediately	  monitored	  at	  405	  nm	  (ex.	  340	  nm)	  for	  10	  minutes.	  Reactions	  had	  final	  concentrations	  of	  30	  
nM	  c-­‐Src,	  500	  µM	  ATP,	  100	  µM	  Na3VO4,	  100	  mM	  Tris	  buffer	  (pH	  8),	  10	  mM	  MgCl2,	  and	  0.01%	  Triton	  X-­‐
100.	   	   For	   KM	   determination,	   the	   kinetic	   values	   were	   obtained	   directly	   from	   nonlinear	   regression	   of	  
substrate-­‐velocity	  curves.	  
	  
For	  ATP,	   reaction	   volumes	  of	   100	  µL	  were	  used	   in	   96-­‐well	   plates.	   85	  µL	  of	   enzyme	   in	  buffer	  mix	  was	  
added	   to	  each	  well	   followed	  by	  10	  µL	  of	   the	  appropriate	  dilution	  of	  ATP	   (typically	  5,	  2.5,	  1.25,	  0.625,	  
0.31,	  0.16,	  0.078,	  0.039,	  0.020,	  and	  0	  mM	  in	  water)	  and	  2.5	  µL	  of	  compound	  12	  (0.4,	  1.2,	  or	  2.4	  mM	  in	  
DMSO).	  The	  reaction	  was	  initiated	  with	  2.5	  µL	  of	  “substrate	  3”	  (1.8	  mM	  in	  DMSO),	  and	  reaction	  progress	  
was	  immediately	  monitored	  at	  405	  nm	  (ex.	  340	  nm)	  for	  10	  minutes.	  Reactions	  had	  final	  concentrations	  
of	  30	  nM	  c-­‐Src,	  45	  µM	  “substrate	  3”,	  100	  µM	  Na3VO4,	  100	  mM	  Tris	  buffer	   (pH	  8),	  10	  mM	  MgCl2,	  and	  
0.01%	   Triton	   X-­‐100.	   	   For	   KM	   determination,	   the	   kinetic	   values	   were	   obtained	   directly	   from	   nonlinear	  
regression	  of	  substrate-­‐velocity	  curves.	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Analytical	  data	   for	  KM	  and	  Lineweaver-­‐Burk	  analysis.	   	  The	  initial	  velocities	  for	  “substrate	  3”	  or	  ATP	  in	  
the	  presence	  of	  inhibitor	  12	  were	  determined	  (n	  =	  4),	  and	  the	  average	  velocities	  were	  used	  to	  generate	  
substrate-­‐velocity	   curves.	   	   Lineweaver-­‐Burk	   plots	   were	   generated	   by	   plotting	   the	   reciprocal	   of	   the	  
average	  initial	  rates	  as	  a	  function	  of	  1/[“substrate	  3”]	  or	  1/[ATP]	  and	  performing	  linear	  regression.	  
	  
Substrate	  KM	  and	  Vmax	  at	  varied	  inhibitor	  concentrations:	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Global	  fit	  data	  for	  substrate	  KM	  data:	  
	  	   R2	  
competitive	   0.993	  
non-­‐competitive	   0.891	  
uncompetitive	   0.888	  
	  
Both	  the	  global	  fit	  and	  KM	  /	  Vmax	  data	  are	  most	  consistent	  with	  a	  substrate-­‐competitive	  mode	  of	  action.	  
	  
ATP	  KM	  and	  Vmax	  at	  varied	  inhibitor	  concentrations:	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Global	  fit	  data	  for	  ATP	  KM	  data:	  	  
	  	   R2	  
competitive	   0.897	  
non-­‐competitive	   0.999	  
uncompetitive	   0.897	  
	  
Both	  the	  global	  fit	  and	  KM	  /	  Vmax	  data	  are	  most	  consistent	  with	  an	  ATP-­‐non-­‐competitive	  mode	  of	  action.	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Figure	  S1.	  	  Lineweaver-­‐Burk	  plot	  for	  compound	  12	  versus	  “substrate	  3”	  peptide.	  	  The	  lines	  intersect	  on	  





















Figure	  S2.	  	  Lineweaver-­‐Burk	  plot	  for	  compound	  12	  versus	  ATP.	  	  The	  lines	  intersect	  on	  the	  X-­‐axis	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Combination	  studies	  of	  compound	  12	  with	  PP2	  and	  PP5.	  	  The	  continuous	  fluorescence	  assay	  described	  
previously	   was	   used	   to	   determine	   IC50	   for	   12,	   PP2,	   and	   PP5	   with	   c-­‐Src.5	   	   Reactions	   had	   final	  
concentrations	  of	  30	  nM	  c-­‐Src,	  45	  µM	  “substrate	  3”,	  300	  µM	  ATP,	  100	  µM	  Na3VO4,	  100mM	  Tris	  buffer	  
(pH	  8),	  10	  mM	  MgCl2,	  and	  0.01%	  Triton	  X-­‐100.	  The	  initial	  rate	  data	  collected	  was	  used	  for	  determination	  
of	  IC50	  values,	  which	  were	  obtained	  directly	  from	  nonlinear	  regression	  of	  substrate-­‐velocity	  curves	  in	  the	  
presence	  of	  various	  concentrations	  of	  the	   inhibitor.	   	  Each	   inhibitor	   IC50	  value	  was	  determined	  using	  at	  
least	  3	  independent	  experiments	  which	  were	  averaged	  to	  give	  an	  average	  IC50	  ±	  standard	  deviation.	  	  A	  
representative	  curve	  is	  shown	  for	  each	  inhibitor	  with	  c-­‐Src.	  
	  
	  
	   Inhibitor	  12	  c-­‐Src	  IC50	  =	  28	  ±	  14	  µM	   	   	   PP2	  c-­‐Src	  IC50	  =	  181	  ±	  6	  nM	  
















	   	  



















	   PP5	  c-­‐Src	  IC50	  =	  98	  ±	  17	  nM	  



















To	   determine	   if	   additive	   or	   synergistic	   effects	   occurred	  when	   compound	  12	  was	   combined	  with	  ATP-­‐
competitive	  inhibitors,	  single	  point	  assays	  of	  the	  inhibitors	  at	  IC35	  (20	  µM	  inhibitor	  12,	  100	  nM	  PP2,	  and	  
50	  nM	  PP5)	  were	  carried	  out	  using	  the	  procedure	  described	  above.	  	  Initial	  velocity	  was	  measured	  for	  12,	  
PP2,	  and	  PP5	  alone	  as	  well	  as	  for	  combinations	  of	  12	  +	  PP2,	  12	  +	  PP5,	  and	  PP2	  +	  PP5.	  	  The	  ratio	  of	  the	  
initial	   velocity	   in	   the	   presence	   of	   inhibitor(s)	   and	   the	   initial	   velocity	   in	   the	   presence	   of	   no	   inhibitor	  
(DMSO	  control)	  was	  used	  to	  calculate	  percent	  activity	  remaining,	  and	  percent	  inhibition	  was	  calculated	  
as	   100	   -­‐	   percent	   activity	   remaining.	   	   The	   percent	   inhibition	   for	   each	   inhibitor	   and	   combination	   of	  
inhibitors	  was	   determined	  using	   at	   least	   6	   independent	   experiments	  which	  were	   averaged	   to	   give	   an	  
average	  percent	  inhibition	  ±	  standard	  deviation.	  	  The	  predicted	  additivity	  was	  determined	  using	  the	  Bliss	  
equation	  [predicted	  additivity	  =	  (eA	  +	  eB)	  –	  (eA	  *	  eB)].8	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Table	  S5.	  	  Percent	  c-­‐Src	  inhibition	  for	  single	  inhibitors	  and	  combinations	  of	  inhibitors.	  
Inhibitor(s)	   c-­‐Src	  Inhibition	  (%)	   Predicted	  Additivity	  (%)	  
100	  nM	  PP2	   34	  ±	  6	   NA	  
50	  nM	  PP5	   32	  ±	  8	   NA	  
20	  µM	  12	   36	  ±	  10	   NA	  
100	  nM	  PP2	  +	  50	  nM	  PP5	   50	  ±	  3	   55	  
100	  nM	  PP2	  +	  20	  µM	  12	   72	  ±	  6	   58	  
50	  nM	  PP5	  +	  20	  µM	  12	   88	  ±	  5	   56	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Time	  dependence	  control	   for	   compound	  12.	   	  The	  continuous	  fluorescence	  assay	  described	  previously	  
was	  used	  to	  determine	  IC50	  for	  compound	  12	  with	  c-­‐Src	  following	  a	  2	  hour	  incubation	  period.5	  	  85	  µL	  of	  
enzyme	   in	  buffer	  mix	  was	  added	  to	  each	  well	   followed	  by	  2.5	  µL	  of	   the	  appropriate	   inhibitor	  dilution,	  
and	  the	  mixture	  was	  incubated	  for	  2	  hours	  at	  room	  temperature.	  	  Following	  the	  incubation	  period,	  2.5	  
µL	  of	  “substrate	  3”	  was	  added,	  the	  reaction	  was	  initiated	  with	  10	  µL	  of	  ATP,	  and	  reaction	  progress	  was	  
immediately	  monitored.	  	  Reactions	  had	  final	  concentrations	  of	  30	  nM	  c-­‐Src,	  45	  µM	  “substrate	  3”,	  1	  mM	  
ATP,	  100	  µM	  Na3VO4,	  100	  mM	  Tris	  buffer	  (pH	  8),	  10	  mM	  MgCl2,	  and	  0.01%	  Triton	  X-­‐100.	  The	  initial	  rate	  
data	   collected	  was	   used	   for	   determination	   of	   Ki	  values,	   which	   were	   obtained	   directly	   from	   nonlinear	  
regression	  of	  substrate-­‐velocity	  curves	   in	  the	  presence	  of	  various	  concentrations	  of	   the	   inhibitor.	   	  The	  
compound	  12	  Ki	  value	  was	  determined	  using	  3	   independent	  experiments	  which	  were	  averaged	  to	  give	  




2	  h	  incubation	  c-­‐Src	  Ki	  =	  9	  ±	  2	  µM	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VII.	  COMPUTATIONAL	  DOCKING	  MODEL	  
	  
Induced	   fit	  molecular	   docking.	   The	   induced	   fit	   docking	   (IFD)	  workflow	   from	   the	   Schrodinger	   Suite	   of	  
Programs	  was	   used	   to	   flexibly	   dock	   SUB1	   into	   four	   Src	   kinase	   structures	   (PDB	   IDs:	   1YI6,	   1Y57,	   2BDF,	  
2SRC).	  Prime,	  also	  from	  the	  Schrodinger	  Suite	  Programs,	  was	  used	  to	  build	  in	  the	  activation	  loop	  of	  2BDF	  
using	   3DQW	  as	   the	   template	   applying	   default	   parameters.	   Default	   parameters	  were	   used	   for	   IFD	   the	  
docking	   score/glide	   gscore	   along	  with	   visual	   inspection	  was	   employed	   to	   determine	   if	   a	   binding	   pose	  













Contact	  distance	  between	  Arg388	  and	  inhibitor	  12	  is	  3.7	  Å:	  







Ligand	  interactions	  between	  inhibitor	  12	  and	  c-­‐Src:	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VIII.	  	  KINASE	  MUTANT	  PRODUCTION	  
	  
Production	   of	   c-­‐Src	   R388A/A390R	   double	  mutant.	   	  Chicken	   c-­‐Src	   kinase	  domain	   in	  pET28a,	  modified	  
with	  a	  TEV	  protease	  cleavable	  N-­‐terminal	  6x-­‐His	  tag,	  was	  prepared	  as	  previously	  reported.4	  	  	  The	  desired	  
mutations	   were	   added	   to	   this	   plasmid	   using	   iterative	   rounds	   of	   mutagenesis	   using	   the	   Agilent	  
QuikChange	  II	  kit.	  The	  plasmid	  was	  transformed	  by	  electroporation	  into	  Bl21DE3	  electrocompetent	  cells	  
containing	  YopH	  in	  pCDFDuet-­‐1.	  Cell	  growth,	  expression,	  and	  protein	  purification	  were	  performed	  using	  
modified	  literature	  protocols	  for	  expression	  of	  wild-­‐type	  c-­‐Src	  kinase	  domain.4	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IX.	  	  IN	  CELLULO	  CHARACTERIZATION	  OF	  COMPOUND	  12	  
	  
c-­‐Src	  autophosphorylation.	  	  This	  assay	  was	  performed	  by	  ProQinase	  GmbH	  (Freiburg,	  Germany).	  Murine	  
embryonal	   fibroblast	   (MEF)	   cells	   were	   used	   that	   express	   a	   high	   level	   of	   exogenously	   introduced	   full-­‐
length	  Src.	  The	  high	  Src	  expression	  level	  results	  in	  a	  constitutive	  tyrosine	  autophosphorylation	  of	  Src	  at	  
Tyr416.	  MEF-­‐SRC	  cells	  were	  plated	  in	  DMEM	  supplemented	  with	  10%	  FCS	  in	  multiwell	  cell	  culture	  plates.	  
Compound	   incubation	   was	   done	   in	   serum-­‐free	   medium.	   Quantification	   of	   Src	   phosphorylation	   was	  
assessed	   in	   96-­‐well	   plates	   via	   ELISA	   using	   a	   phospho-­‐Src	   specific	   antibody	   and	   a	   secondary	   detection	  
antibody.	  Raw	  data	  were	  converted	  into	  percent	  phosphorylation	  and	  the	  IC50	  value	  was	  determined	  	  
using	   GraphPad	   Prism	   software.	   Each	   concentration	   has	   n	   =	   2	   data	   points	   and	   the	   graph	   below	  
represents	  the	  average	  at	  each	  concentration.	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Cancer	   cell	   growth	   inhibition	   assays.	   	   SK-­‐BR-­‐3	   (ATCC®	  HTB-­‐30™),	  MCF7	   (ATCC®	  HTB-­‐22™),	   T47D	   (ATCC®	  
HTB-­‐133™)	  and	  HT-­‐29	  (ATCC®	  HTB-­‐38™)	  cells	  were	  grown	  and	  maintained	  using	  complete	  growth	  media	  
(DMEM	  for	  SK-­‐BR-­‐3,	  MCF7,	  and	  T47D	  and	  McCoy’s	  5a	  Modified	  Medium	  for	  HT-­‐29,	  supplemented	  with	  
10%	  fetal	  bovine	  serum)	  in	  a	  37°C,	  5%	  CO2,	  humidified	  air	  incubator.	  	  Cells	  were	  then	  plated	  into	  96	  well	  
plates	  in	  complete	  growth	  media	  (100	  µl/well)	  at	  a	  concentration	  of	  5000	  cells	  per	  well	  and	  allowed	  to	  
attach	  overnight.	  The	  cells	  were	  dosed	  with	  compound	  at	  1%	  DMSO	  in	  media	  then	  cultured	  for	  72	  hours	  
prior	  to	  addition	  of	  10	  μl/well	  of	  Cell	  Proliferation	  Reagent	  WST-­‐1	  (Roche)	   for	  SK-­‐BR-­‐3	  and	  HT-­‐29.	  The	  
absorbance	   at	   450	   and	   630	   nm	  was	   read	   on	   a	   Biotek	   Synergy	   4	  multimode	   reader	   after	   1	   hour	   37°C	  
incubation	  and	   the	  delta	   (A450-­‐A630)	  was	  plotted	  against	   the	  average	  of	   the	  vehicle-­‐treated	  wells.	   	   Life	  
Technologies	   CyQUANT	   direct	   cell	   proliferation	   assay	   was	   used	   for	   MCF7	   and	   T47D.	   This	   general	  
procedure	  was	  followed	  for	  all	  cell	  lines	  with	  the	  following	  differences:	  	  Prior	  to	  dosing	  the	  SK-­‐BR-­‐3	  cells,	  
the	  complete	  growth	  media	  was	   removed	  by	  aspiration	  and	   replaced	  with	   compound	  at	  1%	  DMSO	   in	  
base	  media,	  0.5%	  fetal	  bovine	  serum,	  and	  60	  ng/ml	  epidermal	  growth	  factor	  in	  DMEM	  (100	  µl/well).	  	  HT-­‐
29,	  MCF7,	  and	  T47D	  cells	  were	  dosed	  by	  addition	  of	  1	  µl	  of	  100X	  compound	  in	  100%	  DMSO	  to	  complete	  
growth	  media.	  
	  
SK-­‐BR-­‐3	  GI50	  =	  14	  µM	  








     EC50 1.381e-005












HT-­‐29	  GI50	  =	  37	  µM	  








     EC50 3.677e-005










T47D	  GI50	  =	  133	  µM	  








     EC50 0.0001334










MCF7	  GI50	  =	  106	  µM	  









     EC50 0.0001056
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AlphaScreen	  SureFire	  Cell	  Signaling	  Assays.	  SK-BR-3 cells (ATCC) were plated in 96-well plates at 
a density of 1.0–2.0 x 104 cells per well. The cells were grown to 80-90% confluency prior to 
overnight serum-starvation in DMEM, 0.1% BSA. The serum-free media was then removed and 
replaced with DMEM containing 10 µM compound 12 (or PP2) in 1% DMSO. The cells were 
incubated for 60 min prior to addition of EGF (Sigma Aldrich). After incubation, the media was 
removed and 50 µL AlphaScreen lysis buffer (PerkinElmer) was added to each well. The lysates 
were analyzed using the AlphaScreen SureFire assay kit (PerkinElmer) according to the 
manufacturer’s protocol. For each compound, n = 3. 
	  
	   	   	  
	  
	  












































































X.	  	  REFERENCES	  
	  
1. Maiti,	  D.;	  Buchwald,	  S.	  L.	  J.	  Am.	  Chem.	  Soc.	  2009,	  131,	  17423.	  
2. Songyang,	  Z.;	  Carraway	  III,	  K.	  L.;	  Eck,	  M.	  J.;	  Harrison,	  S.	  C.;	  Feldman,	  R.	  A.;	  Mohammadi,	  M.;	  
Schlessinger,	  J.;	  Hubbard,	  S.	  R.;	  Smith,	  D.	  P.;	  Eng,	  C.;	  Lorenzo,	  M.	  J.;	  Ponder,	  B.	  A.	  J.;	  Mayer,	  B.	  J.;	  
Cantley,	  L.	  C.	  Nature	  1995,	  373,	  536.	  
3. Soellner,	  M.	  B.;	  Rawls,	  K.	  A.;	  Grundner,	  C.;	  Alber,	  T.;	  Ellman,	  J.	  A.	  J.	  Am.	  Chem.	  Soc.	  2007,	  129,	  9613.	  
4. Seeliger,	  M.A.;	  Young,	  M.;	  Henderson,	  M.	  N.;	  Pellicena,	  P.;	  King,	  D.S.;	  Falick,	  A.	  M.;	  Kuriyan,	  J.	  Protein	  
Sci.	  2005,	  14,	  3135.	  
5. Wang,	  Q.;	  Cahill,	  S.	  M.;	  Blumenstein,	  M.;	  Lawrence,	  D.	  S.	  J.	  Am.	  Chem.	  Soc.	  2006,	  128,	  1808.	  
6. Carna	  Biosciences,	  <http://www.carnabio.com/output/pdf/ProfilingProfilingBook_en.pdf>.	  
7. Kwarcinski,	  F.	  E.;	  Fox,	  C.	  C.;	  Steffey,	  M.	  E.;	  Soellner,	  M.	  B.	  ACS	  Chem.	  Biol.	  2012,	  7,	  1910.	  
8. Berenbaum,	  M.	  C.	  Adv.	  Cancer	  Res.	  1981,	  35,	  269.	  
	  
	  
	  
